Company Announcements

IQE plc: Total Voting Rights and Block Admission

Source: RNS
RNS Number : 6133U
IQE PLC
01 July 2024
 

IQE plc

 

 

Total Voting Rights and Block Admission Return

 

 

Cardiff, UK

1 July 2024

 

 

("IQE" or the "Company")

 

Total Voting Rights

As at 30 June 2024, the Company's issued share capital consisted of 966,625,229 ordinary shares of 1 pence each ("Ordinary Shares"). The Company holds 4,115 Ordinary Shares in treasury. Therefore the total number Ordinary Shares with voting rights in the Company is 966,621,114.

 

Shareholders may use this figure (966,621,114) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Block Admission Return

The Company hereby provides an update to its block admission filed on 24 January 2024.

 

Name of company:

IQE plc



Name of scheme:

All employee share option plan



Period of return:

1 January 2024 to 30 June 2024



Number of Ordinary Shares not issued under scheme at the end of the last period:

5,518,704



Number of Ordinary Shares issued under scheme during period:

5,106,537



Number of Ordinary Shares cancelled under the scheme during period:

Nil



Number of Ordinary Shares added to the scheme during period:

16,000,000



Balance of Ordinary Shares under scheme not yet issued at end of period:

 

16,412,167

Number and class of Ordinary Shares originally admitted under scheme and the date of admission:

1,000,000 Ordinary Shares (4 Dec 2009)

2,000,000 Ordinary Shares (11 Oct 2010)

5,000,000 Ordinary Shares (8 Nov 2010)

8,000,000 Ordinary Shares (5 Apr 2011)

6,000,000 Ordinary Shares (16 May 2012)

16,000,000 Ordinary shares (19 Jun 2012)

8,000,000 Ordinary shares (12 Aug 2014)

8,000,000 Ordinary shares (3 Dec 2015)

12,000,000 Ordinary shares (20 April 2017)

14,000,000 Ordinary shares (12 June 2018)

12,000,000 Ordinary shares (25 January 2019)

3,000,000 Ordinary shares (25 January 2020)

8,000,000 Ordinary shares (4 May 2021)

16,000,000 Ordinary shares (6 February 2024)

 

Contacts:

 

IQE plc

+44 (0) 29 2083 9400

Americo Lemos

Jutta Meier

Amy Barlow

           

Peel Hunt (Nomad and Joint Broker)

+44 (0) 20 7418 8900

Ben Cryer

Kate Bannatyne

Adam Telling

           

Numis (Joint Broker)

+44 (0) 20 7260 1000

Simon Willis

Hugo Rubinstein

Iqra Amin

 

Headland Consultancy (Financial PR)
+ 44 (0) 20 38054822

Andy Rivett-Carnac: +44 (0) 7968 997 365

Chloe Francklin: +44 (0)78 3497 4624

 

ABOUT IQE

http://iqep.com

 

 

IQE is the leading global supplier of advanced compound semiconductor wafers and materials solutions that enable a diverse range of applications across:

 

·    Smart Connected Devices

·    Communications Infrastructure

·    Automotive and Industrial

·    Aerospace and Security

 

As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in this market which has high barriers to entry. IQE supplies the global market and is enabling customers to innovate at chip and OEM level. By leveraging the Group's intellectual property portfolio including know-how and patents, it produces epitaxy wafers of superior quality, yield and unit economics.


IQE is headquartered in Cardiff UK, with employees across eight manufacturing locations in the UK, US and Taiwan, and is listed on the AIM Stock Exchange in London.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBFLFBZDLFBBD